Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?
By Max Rex, Associate Consultant Email: mrex@partners4access.com Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green light by the European Medicines Agency on 19th May. The therapy has previously been approved in the US and Japan, and has already generated sales of over $500 million dollars…